Arbutus Biopharma Corporation (NASDAQ:ABUS) is set to post its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Arbutus Biopharma Corporation to post earnings of ($0.37) per share for the quarter.
Arbutus Biopharma Corporation (NASDAQ:ABUS) opened at 6.05 on Monday. Arbutus Biopharma Corporation has a 1-year low of $2.35 and a 1-year high of $8.25. The stock has a 50 day moving average price of $6.32 and a 200-day moving average price of $4.31. The firm’s market cap is $332.91 million.
A number of equities analysts have recently commented on ABUS shares. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Wednesday, September 13th. Zacks Investment Research upgraded shares of Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 10th. ValuEngine upgraded shares of Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. Wedbush reiterated an “outperform” rating and set a $9.00 price target on shares of Arbutus Biopharma Corporation in a report on Wednesday, September 20th. Finally, JMP Securities reiterated an “outperform” rating and set a $13.00 price target (up previously from $12.00) on shares of Arbutus Biopharma Corporation in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $15.00.
COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/10/30/arbutus-biopharma-corporation-abus-set-to-announce-earnings-on-wednesday.html.
In related news, insider Michael J. Sofia sold 30,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $3.70, for a total value of $111,000.00. Following the transaction, the insider now owns 1,563,403 shares in the company, valued at $5,784,591.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Michael J. Sofia sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. The disclosure for this sale can be found here. 10.00% of the stock is owned by insiders.
An institutional investor recently raised its position in Arbutus Biopharma Corporation stock. Vanguard Group Inc. grew its stake in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) by 2.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 77,413 shares of the biopharmaceutical company’s stock after purchasing an additional 2,035 shares during the period. Vanguard Group Inc. owned approximately 0.14% of Arbutus Biopharma Corporation worth $279,000 as of its most recent filing with the Securities and Exchange Commission. 67.00% of the stock is owned by institutional investors.
Arbutus Biopharma Corporation Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
What are top analysts saying about Arbutus Biopharma Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arbutus Biopharma Corporation and related companies.